





Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

INN	Emtricitabine + rilpivirine + tenofovir
ATC codes	J05AR08
Medicine type	Chemical agent
EML status history	Application rejected in 2015 (TRS 994) for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Wikipedia	Emtricitabine + rilpivirine + tenofovir disoproxil fumarate 
DrugBank	Emtricitabine  , Rilpivirine  , Tenofovir disoproxil fumarate (Tenofovir disoproxil) 

Recommendations

Section Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

